Navigation Links
Delcath To Present At Upcoming Investor Conferences
Date:8/8/2012

NEW YORK, Aug. 8, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that Eamonn P. Hobbs, President and Chief Executive Officer, is scheduled to present an overview of the Company's business strategy and recent corporate developments at the following investor conferences in August:

  • The Wedbush PacGrow Lifesciences Management Access Conference in New York City on August 14, 2012 at 9:45 AM ET.
  • The Canaccord Genuity Growth Conference in Boston, MA on August 15, 2012 at 4:00 PM ET.
  • A live webcast and subsequent archived replay of the presentations will be available at http://www.delcath.com/investors/events/.  The archived replays will be available for 90 days after the respective live events.

    About Delcath Systems
    Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com.

    Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, for the chemosaturation system in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

    Media Contact:Doug Sherk/Gregory Gin

    Janine McCargoEVC Group

    EVC Group415-568-4887/646-445-4801

    646-688-0425 

     


    '/>"/>
    SOURCE Delcath Systems, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems, Inc. Secures $20 Million Credit Facility
    2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
    3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
    4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
    5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
    6. Delcath Announced Changes To Board Of Directors
    7. Delcath To Present At JMP Securities Healthcare Conference On July 12
    8. Delcath To Conduct Second Quarter 2012 Results Conference Call
    9. Delcath Reports Second Quarter 2012 Financial Results And Highlights Recent Accomplishments
    10. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
    11. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
    (Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
    (Date:5/3/2016)... , May 3, 2016  Specialty Silicone ... tool that shows how a cleanroom works. The ... discussions about science and technology. ... "As a technology company, SSF enthusiastically supports the ... help educators foster the next generation of innovators. ...
    Breaking Medicine Technology:
    (Date:5/4/2016)... ... May 04, 2016 , ... ... interview techniques, seeks to add a deeper understanding of the program, policy or ... and each answers different yet important questions. , In a new brief released ...
    (Date:5/4/2016)... ... May 04, 2016 , ... Cirius, a provider of ... innovative Secure Messaging platform, which includes secure, private messaging, large file sharing, secure ... portfolio of patents around innovative features for securing, tracking, and controlling messages for ...
    (Date:5/4/2016)... Camas, WA (PRWEB) , ... ... ... Agencies, a full service insurance provider serving families of Camas and Vancouver, ... The current campaign fundraises for the National Breast Cancer Foundation and their ...
    (Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is set to return to the esteemed Quaker Ridge Golf Club in Scarsdale, ...
    (Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
    Breaking Medicine News(10 mins):